Christine J Harrison

List of Publications by Year
in descending order

195	21,011	10389	10445
papers	citations	72 h-index	139 g-index

203	203	203	13508
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial. Blood, 1998, 92, 2322-2333.	1.4	2,441
2	Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 2010, 116, 354-365.	1.4	1,661
3	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	7.2	1,023
4	The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 2001, 98, 1312-1320.	1.4	849
5	Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood, 2007, 109, 3189-3197.	1.4	655
6	Burkitt's lymphoma. Lancet, The, 2012, 379, 1234-1244.	13.7	486
7	Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood, 2009, 114, 2688-2698.	1.4	445
8	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 2009, 114, 2489-2496.	1.4	383
9	A simple, robust, validated and highly predictive index for the determination of riskâ€directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. British Journal of Haematology, 1999, 107, 69-79.	2.5	376
10	Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncology, The, 2010, 11, 429-438.	10.7	338
11	Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 2010, 115, 1006-1017.	1.4	305
12	PHF6 mutations in T-cell acute lymphoblastic leukemia. Nature Genetics, 2010, 42, 338-342.	21.4	282
13	Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia, 2005, 19, 2130-2138.	7.2	277
14	Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature, 2014, 508, 98-102.	27.8	261
15	Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12. Journal of Clinical Oncology, 2010, 28, 2674-2681.	1.6	256
16	Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood, 2007, 110, 1112-1115.	1.4	250
17	Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nature Genetics, 2010, 42, 492-494.	21.4	248
18	Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood, 2013, 122, 2622-2629.	1.4	248

#	Article	IF	Citations
19	Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia, 2003, 17, 700-706.	7.2	216
20	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood, 2014, 124, 3420-3430.	1.4	209
21	Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood, 2007, 109, 2327-2330.	1.4	200
22	Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. British Journal of Haematology, 2009, 144, 147-156.	2.5	196
23	Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood, 2007, 109, 3451-3461.	1.4	188
24	Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. British Journal of Haematology, 2004, 125, 552-559.	2.5	184
25	A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood, 2014, 124, 1434-1444.	1.4	178
26	An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia, 2014, 28, 1015-1021.	7.2	175
27	Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood, 2009, 113, 646-648.	1.4	169
28	A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood, 2009, 113, 100-107.	1.4	167
29	Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial. British Journal of Haematology, 2011, 155, 366-376.	2.5	167
30	Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood, 2003, 102, 2756-2762.	1.4	165
31	Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980â€“2001. Leukemia, 2010, 24, 406-418.	7.2	158
32	Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia, 2003, 17, 547-553.	7.2	153
33	Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia. Haematologica, 2015, 100, 1301-1310.	3.5	151
34	Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood, 2008, 111, 1575-1583.	1.4	149
35	Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 34-43.	1.6	147
36	Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8167-8172.	7.1	146

#	Article	IF	Citations
37	Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia, 2006, 20, 1610-1617.	7.2	141
38	Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica, 2013, 98, 1081-1088.	3.5	139
39	Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. British Journal of Haematology, 2005, 129, 520-530.	2.5	137
40	Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood, 2011, 117, 2129-2136.	1.4	133
41	Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia. Cancer Research, 2008, 68, 6803-6809.	0.9	129
42	IKZF1 status as a prognostic feature in BCR-ABL1â€“positive childhood ALL. Blood, 2014, 123, 1691-1698.	1.4	129
43	Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood, 2007, 109, 4641-4647.	1.4	126
44	IGH@ Translocations, CRLF2 Deregulation, and Microdeletions in Adolescents and Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2012, 30, 3100-3108.	1.6	120
45	Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. British Journal of Haematology, 2001, 113, 103-114.	2.5	118
46	Risk-Directed Treatment Intensification Significantly Reduces the Risk of Relapse Among Children and Adolescents With Acute Lymphoblastic Leukemia and Intrachromosomal Amplification of Chromosome 21: A Comparison of the MRC ALL97/99 and UKALL2003 Trials. Journal of Clinical Oncology, 2013, 31, 3389-3396.	1.6	111
47	Detection of prognostically relevant genetic abnormalities in childhood Bâ€cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlinâ€FrankfÃ¼rtâ€MÃ¼nster study group. British Journal of Haematology, 2010, 151, 132-142.	2.5	108
48	Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood, 2011, 117, 6848-6855.	1.4	108
49	EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood, 2016, 127, 2214-2218.	1.4	108
50	Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia, 2003, 17, 2249-2250.	7.2	103
51	Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood, 2016, 128, 911-922.	1.4	103
52	Evaluation of multiplex ligationâ€dependent probe amplification as a method for the detection of copy number abnormalities in Bâ€cell precursor acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2010, 49, 1104-1113.	2.8	101
53	Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease. Blood, 2015, 125, 1383-1386.	1.4	97
54	Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. Oncogene, 2007, 26, 4306-4318.	5.9	95

#	Article	IF	Citations
55	Molecular tracking of leukemogenesis in a triplet pregnancy. Blood, 2001, 98, 478-482.	1.4	94
56	Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia, 2002, 16, 776-784.	7.2	94
57	Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Reviews in Clinical and Experimental Hematology, 2002, 6, 91-113.	0.1	93
58	Chronic myeloid leukemia: reminiscences and dreams. Haematologica, 2016, 101, 541-558.	3.5	92
59	Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia, 2012, 26, 2204-2211.	7.2	91
60	INVESTIGATION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA BY MOLECULAR ANALYSIS.. British Journal of Haematology, 1999, 105, 7-24.	2.5	88
61	Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. Blood, 2010, 115, 3553-3558.	1.4	87
62	IGH@ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome. Journal of Clinical Oncology, 2014, 32, 1453-1462.	1.6	87
63	Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-MÃ¼nster AML-study group. Blood, 2013, 122, 2704-2713.	1.4	86
64	Prenatal origin of hyperdiploid acute lymphoblastic leukemia in identical twins. Leukemia, 2003, 17, 2202-2206.	7.2	84
65	The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica, 2010, 95, 1221-1225.	3.5	84
66	Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. British Journal of Haematology, 1995, 91, 104-108.	2.5	82
67	A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia, 2010, 24, 1362-1364.	7.2	82
68	Genetic aberrations in paediatric acute leukaemias and implications for management of patients. Lancet Oncology, The, 2010, 11, 880-889.	10.7	82
69	Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia, 2004, 18, 693-702.	7.2	81
70	Variable breakpoints target PAX5 in patients with dicentric chromosomes: A model for the basis of unbalanced translocations in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17050-17054.	7.1	77
71	t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica, 2014, 99, 865-872.	3.5	77
72	The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukaemia. Blood Reviews, 2001, 15, 49-59.	5.7	76

#	Article	IF	Citations
73	Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2017, 35, 660-667.	1.6	76
74	Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-MÃ¼nster Study Group. Journal of Clinical Oncology, 2015, 33, 4247-4258.	1.6	75
75	ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nature Communications, 2015, 6, 5794.	12.8	75
76	Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia, 2005, 19, 1634-1642.	7.2	73
77	Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS). British Journal of Haematology, 1990, 75, 16-25.	2.5	71
78	Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). British Journal of Haematology, 2004, 124, 33-46.	2.5	71
79	The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia: a valuable resource for patient management. British Journal of Haematology, 2001, 113, 3-10.	2.5	69
80	Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica, 2009, 94, 1708-1713.	3.5	68
81	Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia. Blood, 2006, 108, 3560-3563.	1.4	67
82	Molecular cytogenetic characterization ofTCF3 (E2A)/19p13.3 rearrangements in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2007, 46, 478-486.	2.8	67
83	Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. British Journal of Haematology, 2002, 117, 427-435.	2.5	65
84	Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes and Cancer, 2009, 48, 624-636.	2.8	65
85	Scanning electron microscopy of the G-banded human karyotype. Experimental Cell Research, 1981, 134, 141-153.	2.6	64
86	Common region of deletion on the long arm of chromosome 6 in non-Hodgkin's lymphoma and acute lymphoblastic leukaemia. Genes Chromosomes and Cancer, 1994, 10, 286-288.	2.8	64
87	Intrachromosomal amplification of chromosome 21 (iAMP21) may arise from a breakageâ€“fusionâ€“bridge cycle. Genes Chromosomes and Cancer, 2007, 46, 318-326.	2.8	64
88	Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. Journal of Clinical Oncology, 2019, 37, 770-779.	1.6	64
89	Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. British Journal of Haematology, 2002, 117, 306-314.	2.5	62
90	t(7;12)(q36;p13), a new recurrent translocation involvingETV6 in infant leukemia. Genes Chromosomes and Cancer, 2000, 29, 325-332.	2.8	60

#	Article	IF	Citations
91	t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood, 2008, 111, 387-391.	1.4	59
92	The complex genomic profile of ETV6â€RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1. Genes Chromosomes and Cancer, 2008, 47, 1118-1125.	2.8	58
93	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood, 2011, 117, 7102-7111.	1.4	58
94	Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nature Communications, 2018, 9, 1340.	12.8	58
95	The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica, 2013, 98, 945-952.	3.5	54
96	A Fluorescence in Situ Hybridization Map of 6q Deletions in Acute Lymphocytic Leukemia. Cancer Research, 2004, 64, 4089-4098.	0.9	49
97	Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations. Blood, 2014, 124, 3577-3582.	1.4	49
98	Characterisation of the genomic landscape of CRLF2â€rearranged acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2017, 56, 363-372.	2.8	49
99	Advances in Bâ€cell Precursor Acute Lymphoblastic Leukemia Genomics. HemaSphere, 2018, 2, e53.	2.7	49
100	Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. Blood Advances, 2019, 3, 148-157.	5.2	48
101	Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica, 2009, 94, 1024-1028.	3.5	47
102	Del (9q) AML: clinical and cytological characteristics and prognostic implications. British Journal of Haematology, 2005, 129, 210-220.	2.5	44
103	The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial. Blood, 1998, 92, 2322-2333.	1.4	44
104	Heterogeneous breakpoints in patients with acute lymphoblastic leukemia and the dic(9;20)(p11Â13;q11) show recurrent involvement of genes at 20q11.21. Haematologica, 2009, 94, 1164-1169.	3.5	43
105	Targeting signaling pathways in acute lymphoblastic leukemia: new insights. Hematology American Society of Hematology Education Program, 2013, 2013, 118-125.	2.5	42
106	Pediatric home mechanical ventilation: A Canadian Thoracic Society clinical practice guideline executive summary. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 7-36.	0.5	41
107	Deletion of a common region on the long arm of chromosome 6 in acute lymphoblastic leukaemia. Genes Chromosomes and Cancer, 1994, 10, 26-29.	2.8	39
108	Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. British Journal of Haematology, 2012, 158, 772-777.	2.5	39

#	Article	IF	Citations
109	Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge. Genes, 2021, 12, 924.	2.4	39
110	Fluorescence In Situ Hybridization Analysis of Masked (8;21)(q22;q22) Translocations. Cancer Genetics and Cytogenetics, 1999, 112, 15-20.	1.0	35
111	Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results. British Journal of Haematology, 2003, 120, 944-952.	2.5	32
112	Acute Lymphoblastic Leukemia. Clinics in Laboratory Medicine, 2011, 31, 631-647.	1.4	31
113	Constitutional abnormalities of chromosome 21 predispose to iAMP21-acute lymphoblastic leukaemia. European Journal of Medical Genetics, 2016, 59, 162-165.	1.3	31
114	Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABLâ€class fusion. British Journal of Haematology, 2020, 191, 844-851.	2.5	31
115	Acute lymphoblastic leukaemia. Best Practice and Research in Clinical Haematology, 2001, 14, 593-607.	1.7	30
116	Digital Multiplex Ligation-Dependent Probe Amplification for Detection of Key Copy Number Alterations in T- and B-Cell Lymphoblastic Leukemia. Journal of Molecular Diagnostics, 2017, 19, 659-672.	2.8	30
117	Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL. Blood, 2018, 131, 421-425.	1.4	30
118	Analysis of a breakpoint cluster reveals insight into the mechanism of intrachromosomal amplification in a lymphoid malignancy. Human Molecular Genetics, 2011, 20, 2591-2602.	2.9	29
119	Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature. Cancer Genetics, 2013, 206, 162-173.	0.4	29
120	THE MANAGEMENT OF PATIENTS WITH LEUKAEMIA: THE ROLE OF CYTOGENETICS IN THIS MOLECULAR ERA. British Journal of Haematology, 2000, 108, 19-30.	2.5	28
121	Comparative expressed sequence hybridization studies of high-hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2004, 41, 191-202.	2.8	28
122	Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. Experimental Hematology, 2017, 54, 40-50.	0.4	28
123	Philadelphia-positive metaphases in the marrow after bone marrow transplantation for chronic granulocytic leukemia. American Journal of Hematology, 1986, 22, 199-204.	4.1	27
124	Methylation of tumour suppressor gene promoters in the presence and absence of transcriptional silencing in high hyperdiploid acute lymphoblastic leukaemia. British Journal of Haematology, 2009, 144, 838-847.	2.5	27
125	Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. Epigenetics, 2015, 10, 717-726.	2.7	26
126	SH2B3 inactivation through CN-LOH 12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain. Leukemia, 2019, 33, 1881-1894.	7.2	26

#	Article	IF	Citations
127	t(14;19)(q32;q13): A recurrent translocation in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2004, 39, 88-92.	2.8	25
128	Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?. Blood Advances, 2017, 1, 1473-1477.	5.2	25
129	A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood, 2020, 135, 1438-1446.	1.4	25
130	Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia, 2022, 36, 625-636.	7.2	25
131	Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials. Lancet Haematology,the, 2021, 8, e828-e839.	4.6	25
132	Multiplex Fluorescence In Situ Hybridization and Cross Species Color Banding of a Case of Chronic Myeloid Leukemia in Blastic Crisis with a Complex Philadelphia Translocation. Cancer Genetics and Cytogenetics, 2000, 116, 105-110.	1.0	24
133	Retinoblastoma in association with the chromosome breakage syndromes Fanconi's anaemia and Bloom's syndrome: clinical and cytogenetic findings. Clinical Genetics, 1995, 47, 311-317.	2.0	24
134	The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A. Scientific Reports, 2015, 5, 15065.	3.3	24
135	MLL translocations with concurrent 3? deletions: Interpretation of FISH results. Genes Chromosomes and Cancer, 2004, 41, 266-271.	2.8	23
136	The structural basis for C-banding. Chromosoma, 1985, 91, 363-368.	2.2	22
137	Abnormalities of the der(12)t(12;21) in ETV6â€RUNX1 acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2013, 52, 202-213.	2.8	22
138	Is trisomy 5 a distinct cytogenetic subgroup in acute lymphoblastic leukemia?. Cancer Genetics and Cytogenetics, 2004, 148, 159-162.	1.0	21
139	Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood, 2012, 120, 4441-4443.	1.4	21
140	IGH@ translocations co-exist with other primary rearrangements in B-cell precursor acute lymphoblastic leukemia. Haematologica, 2014, 99, 1334-1342.	3.5	20
141	Analysis of ETV6/AML1 abnormalities in acute lymphoblastic leukaemia: incidence, alternative spliced forms and minimal residual disease value. British Journal of Haematology, 2000, 111, 1071-1079.	2.5	20
142	14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia. Blood, 2021, 138, 773-784.	1.4	19
143	Cross-species color banding in ten cases of myeloid malignancies with complex karyotypes. Genes Chromosomes and Cancer, 2001, 30, 15-24.	2.8	18
144	Complex chromosomal abnormalities in utero , 5â€ƒyears before leukaemia*. British Journal of Haematology, 2004, 126, 307-312.	2.5	18

#	Article	IF	Citations
145	Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. Haematologica, 2016, 101, 951-958.	3.5	18
146	Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia. Journal of Molecular Diagnostics, 2020, 22, 629-639.	2.8	18
147	The genetics of childhood acute lymphoblastic leukaemia. Best Practice and Research in Clinical Haematology, 2000, 13, 427-439.	1.7	17
148	ETV6/RUNX1 fusion at diagnosis and relapse: Some prognostic indications. Genes Chromosomes and Cancer, 2005, 43, 54-71.	2.8	17
149	CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response. Haematologica, 2017, 102, 736-745.	3.5	17
150	Involvement of the MLL gene in T-lineage acute lymphoblastic leukemia. Blood, 2002, 100, 2273-2273.	1.4	16
151	The karyotype of Alligator mississippiensis, and chromosomal mapping of the ZFY/X homologue, Zfc. Chromosoma, 1994, 103, 502-507.	2.2	15
152	Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and reâ€sensitization by JNK inhibition. British Journal of Haematology, 2015, 171, 595-605.	2.5	15
153	PCR amplicons identify widespread copy number variation in human centromeric arrays and instability in cancer. Cell Genomics, 2021, 1, 100064.	6.5	14
154	Characterization of unusual <scp>iAMP21</scp> Bâ€lymphoblastic leukemia (<scp>iAMP21â€ALL</scp>) from the Mayo Clinic and Children's Oncology Group. Genes Chromosomes and Cancer, 2022, 61, 710-719.	2.8	14
155	A cell line from Wilms' tumour with deletion in short arm of chromosome 11. International Journal of Cancer, 1987, 40, 499-504.	5.1	13
156	Modeling the molecular consequences of unbalanced translocations in cancer: Lessons from acute lymphoblastic leukemia. Cell Cycle, 2009, 8, 2175-2184.	2.6	13
157	Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Haematologica, 2018, 103, 634-644.	3.5	13
158	MLPA and DNA index improve the molecular diagnosis of childhood B-cell acute lymphoblastic leukemia. Scientific Reports, 2020, 10, 11501.	3.3	13
159	HLA-DPB1 supertype-associated protection from childhood leukaemia: relationship to leukaemia karyotype and implications for prevention. Cancer Immunology, Immunotherapy, 2008, 57, 53-61.	4.2	12
160	The B-13 hepatocyte progenitor cell resists pluripotency induction and differentiation to non-hepatocyte cells. Toxicology Research, 2013, 2, 308.	2.1	12
161	<scp>MYB</scp> rearrangements and overâ€expression in Tâ€cell acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2021, 60, 482-488.	2.8	12
162	Single nucleotide polymorphism arrayâ€based signature of low hypodiploidy in acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2021, 60, 604-615.	2.8	12

#	Article	IF	Citations
163	Genetic characterisation of childhood Bâ€otherâ€acute lymphoblastic leukaemia in UK patients by fluorescence inÂsitu hybridisation and Multiplex Ligationâ€dependent Probe Amplification. British Journal of Haematology, 2022, 196, 753-763.	2.5	12
164	Acute Lymphoblastic Leukaemia. Methods in Molecular Biology, 2011, 730, 99-117.	0.9	10
165	A structural basis for R- and T-banding: a scanning electron microscopy study. Chromosoma, 1986, 94, 395-402.	2.2	9
166	A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. Cancer Genetics and Cytogenetics, 2007, 173, 17-22.	1.0	9
167	Genetic characterization and therapeutic targeting of MYCâ€rearranged T cell acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 185, 169-174.	2.5	9
168	Immunoglobulin Heavy Chain Locus (IGH@) Translocations in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Incidence and Risk Stratification. Blood, 2012, 120, 1274-1274.	1.4	9
169	Key pathways as therapeutic targets. Blood, 2011, 118, 2935-2936.	1.4	8
170	Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial. Journal of Clinical Oncology, 2022, 40, 4228-4239.	1.6	8
171	Influence of 12-o-tetradecanoylphorbol-13-acetate (TPA) on the susceptibility of K562 to natural cytotoxicity: Evidence for clonal variation in differentiation-induced changes of lytic sensitivity. International Journal of Cancer, 1984, 33, 693-700.	5.1	7
172	IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia. Translational Oncology, 2019, 12, 726-732.	3.7	7
173	Concordance of copy number abnormality detection using SNP arrays and Multiplex Ligation-dependent Probe Amplification (MLPA) in acute lymphoblastic leukaemia. Scientific Reports, 2020, 10, 45.	3.3	7
174	Light and Scanning Electron Microscopy of the Same Metaphase Chromosomes. , 1987, , 189-248.		6
175	SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome. Blood, 2021, 137, 1835-1838.	1.4	6
176	Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14. Blood, 2019, 134, 288-288.	1.4	6
177	Cytogenetics of longâ€term survivors of ETV6â€RUNX1 fusion positive acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2010, 49, 253-259.	2.8	5
178	Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study. Pediatric Blood and Cancer, 2022, 69, e29341.	1.5	5
179	Chromosomal evidence of a common stem cell in acute lymphoblastic leukemia and chronic granulocytic leukemia. Cancer Genetics and Cytogenetics, 1984, 13, 331-336.	1.0	4
180	â€œOnly flesh with its soul â€“ its blood â€“ you must not eatâ€•(Genesis 9.3:4). Paediatrics and Child Health, 2007, 12, 867-868.	0.6	4

#	Article	IF	Citations
181	Primum non nocere is only the beginning. Paediatrics and Child Health, 2007, 12, 379-380.	0.6	4
182	Genomic Analysis Drives Tailored Therapy in Poor Risk Childhood Leukemia. Cancer Cell, 2012, 22, 139-140.	16.8	4
183	Fluorescence In Situ Hybridization (FISH) as a Tool for the Detection of Significant Chromosomal Abnormalities in Childhood Leukaemia. Methods in Molecular Biology, 2009, 538, 29-55.	0.9	4
184	INVESTIGATION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA BY MOLECULAR ANALYSIS. British Journal of Haematology, 1999, 105, 7-24.	2.5	3
185	A diminutive chromosome 21 centromere in acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2006, 167, 78-81.	1.0	2
186	New genetics and diagnosis of childhood B-cell precursor acute lymphoblastic leukemia. Mental Illness, 2011, 3, 4.	0.8	2
187	Section 3: Ethics of initiation of long-term ventilation in children at home. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 16-22.	0.5	2
188	Cytogenetics and Molecular Genetics. , 2017, , 61-98.		2
189	Detection of genomic aberrations in older patients with acute myeloid leukemia. Haematologica, 2005, 90, 147.	3.5	2
190	Advances in Molecular Cytogenetics to Study the Leukemia Genome. Laboratory Medicine, 2007, 38, 527-535.	1.2	1
191	Re: Teenage decision-making in the context of the Jehovah's Witness faith (again). Paediatrics and Child Health, 2008, 13, 332-334.	0.6	1
192	Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials. Blood, 2019, 134, 2746-2746.	1.4	1
193	Cytogenetics of Leukaemia and Lymphoma. , 0, , 492-508.		1
194	Cytogenetic and genomic characterization of cell line ARH77. Cancer Genetics and Cytogenetics, 2008, 181, 40-45.	1.0	0
195	Re: Faith held by Jehovah's Witnesses does not always forbid blood transfusions. Paediatrics and Child Health, 2008, 13, 341-341.	0.6	0